MPNs

A study presented during the 2020 ASH Annual Meeting has suggested that certain driver mutations for myeloproliferative neoplasms can be traced back to when they were acquired as early as in utero.

Luspatercept demonstrated clinical efficacy and a tolerable safety profile in patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who were enrolled in the MEDALIST trial.

Naveen Pemmaraju, MD, discusses the next steps for research in the field of myelofibrosis.

Improvements in spleen volume and total symptom score were clinically meaningful with the addition of navitoclax to ruxolitinib in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

During a Targeted Oncology Case Based Peer Perspectives event, Rami Komrokji, MD, explored the use of ruxolitinib (Jakafi) for the treatment of a 68-year-old female patient with myelofibrosis.

Low-dose ruxolitinib appears effective as treatment of patients with myelofibrosis, improving splenomegaly and symptoms with a daily dose ≤ 10 mg.

Investigators conducted post hoc analyses of the phase 3 JUMP clinical trial to determine how clinical characteristics correlate with response to therapy in patients with myelofibrosis.

John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.

In an interview with Targeted Oncology, John O. Mascarenhas, MD, discussed the evolving role of JAK inhibitors for the treatment of patients with myelofibrosis, including new agents under evaluation in randomized studies and potential combination strategies that may also improve outcomes.

Uday R. Popat, MD, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms.

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.

A rolling submission of a New Drug Application has been initiated for pacritinib, seeking FDA approval for the drug as treatment of patients with myelofibrosis with severe thrombocytopenia.

During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.

A New Drug Application for pacritinib is planned to be submitted for potential accelerated approval from the FDA for the treatment of patients with myelofibrosis and severe thrombocytopenia.

Raajit K. Rampal, MD, PhD, discussed the role of genomics in the treatment landscape of myelofibrosis and the remaining challenges that need to be addressed in order to use this information more effectively to treat patients and improve outcomes.

In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed recent advances for the treatment of patients with MPNs and shared his thoughts on recent hematologic meetings and the growing role of social media during the COVID-19 pandemic.

Ruben Mesa, MD, shares highlights from his presentation on the role of JAK inhibitors in myelofibrosis during the first annual Texas Virtual MPN Workshop and Meeting.

In an interview with Targeted Oncology, Prithviraj Bose, MD, discussed the disease outcomes for patients with essential thrombocythemia, as well as the unmet needs and therapeutic strategies available in this space.

Prognostic factors in patients with myelofibrosis treated with a myeloablative busulfan/fludarabine conditioning regimen prior to allogeneic stem cell transplantation in a single-institution analysis showed that a time from diagnosis to transplant of more than 12 months was associated with poorer overall survival and displayed a trend toward higher non-relapse mortality.

JAK inhibitors continue to make a splash in the treatment landscape of MPNs and are be evaluated in multiple clinical trials, and the advancement of these agents should be recognized in honor of MPN Awareness Day.

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.

Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.

Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.

In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.